Although preclinical studies suggest that PD-1 blockade (e.g., with nivolumab) may restore IL-10 function, the potential autoimmune risks associated with such interventions in COPD patients warrant cautious interpretation. Here, IL10 is linked to chronic obstructive pulmonary disease.